Early treatment gives the developing brain a chance to wire itself more typically.
For generations, a quiet fear has shadowed the decision to medicate a troubled child: that the cure might seed a later addiction. A landmark review by Massachusetts General Hospital, drawing on twenty-six studies and nearly six million lives, now turns that fear on its head — finding that early, sustained psychiatric treatment does not open the door to substance use disorder, but closes it. The evidence suggests that the most protective thing medicine can offer a child at risk is not restraint, but timely intervention.
- A long-standing clinical anxiety — that psychiatric medication might prime young people for addiction — has quietly discouraged treatment for millions of children with ADHD, depression, and psychotic disorders.
- A sweeping MGH review of twenty-six studies covering nearly six million individuals found the opposite: medication treatment reduced substance use disorder risk by thirty to thirty-five percent, with no studies showing harm.
- The protective effect was sharpest when treatment began before age nine and continued consistently — suggesting that the timing and duration of care matter as much as the decision to treat at all.
- Critical gaps remain: anxiety, conduct disorder, PTSD, and bipolar disorder are largely unstudied in this context, leaving clinicians without guidance for a significant portion of the pediatric psychiatric population.
- A follow-up NIH-funded study is now tracking whether these protections extend into young adulthood, with a particular focus on opioid use disorder — reframing addiction prevention as a task that may begin in the pediatric clinic, years before any substance is encountered.
Half of all psychiatric illness emerges before age eighteen, and three-quarters before twenty-four. For decades, that reality has been shadowed by a clinical worry: that medicating young minds might inadvertently set them on a path toward substance abuse. A team at Massachusetts General Hospital, led by Timothy Wilens, chief of child and adolescent psychiatry, has spent years testing whether that fear holds up — and found that it does not.
Reviewing twenty-six long-term studies spanning nearly six million individuals, Wilens and his colleagues discovered that psychiatric medication not only failed to increase substance use disorder risk in children and adolescents — it reduced it. For ADHD, major depressive disorder, and psychotic disorders, treatment cut the likelihood of later substance use disorder by roughly thirty to thirty-five percent. Not one of the studies they examined demonstrated harm.
The protective effect was most pronounced when treatment began early — before age nine — and continued over time. The finding carries an intuitive logic: addressing a psychiatric condition consistently during development gives the brain a better chance to mature without the compounding burden of untreated illness. It was already known that untreated childhood psychiatric disorders roughly double or triple the risk of later substance abuse; the new question was whether medication interrupted that trajectory or accelerated it. The literature answered clearly: it interrupts it.
Significant gaps remain. No studies examined whether medication for anxiety, conduct disorder, PTSD, or personality disorders affected substance use risk, and data on bipolar disorder were too sparse to interpret. But the evidence that does exist points in a single direction.
Wilens and his team are now conducting a second NIH-funded study examining whether these protections extend to adolescents and young adults aged sixteen to thirty, with particular attention to opioid use disorder. The broader implication is quietly radical: substance use disorder prevention may begin not in addiction medicine, but in the pediatric psychiatry clinic — years before a child ever encounters a substance at all.
Half of all psychiatric illness emerges by age eighteen. Three-quarters of it arrives by twenty-four. These numbers have long shadowed pediatric medicine with a particular anxiety: the fear that medicating young minds might set them on a path toward substance abuse. A team at Massachusetts General Hospital has now spent years examining whether that fear is justified, and they have arrived at an answer that inverts the worry entirely.
The researchers, led by Timothy Wilens, the chief of child and adolescent psychiatry at MGH, reviewed twenty-six long-term studies spanning nearly six million individuals. What they found was striking. Not only did psychiatric medication fail to increase the risk of substance use disorder in children and adolescents—it actually reduced it. For three conditions in particular—ADHD, major depressive disorder, and psychotic disorders—medication treatment cut the risk of later developing a substance use disorder by roughly thirty to thirty-five percent.
Wilens and his team had begun with a straightforward clinical question. It was already well established that untreated psychiatric illness in children roughly doubles or triples the likelihood of developing substance abuse problems down the line. The question was whether treating those disorders with medication might somehow accelerate that trajectory, or whether treatment might instead interrupt it. The literature suggested the latter. Most of the studies they examined showed either that treatment reduced substance use or produced no effect at all. None demonstrated harm.
The protective effect was strongest when treatment began early and continued over time. Children who started medication before age nine and remained on treatment for extended periods showed the most robust protection against later substance use disorder. This pattern held especially true for ADHD, where the data were most abundant. The finding makes intuitive sense, Wilens noted: catching a psychiatric condition young and treating it consistently gives the brain a better chance to develop without the compounding damage of untreated illness.
The research team acknowledged significant gaps in the literature. They found no studies examining whether medication for anxiety, conduct disorder, personality disorder, or post-traumatic stress disorder affected later substance use risk. The data on bipolar disorder were too sparse to draw conclusions. But the evidence that did exist pointed in a single direction: early identification and sustained treatment of childhood psychiatric illness appears to be protective, not permissive.
Wilens and his colleagues are now conducting a second NIH-funded study examining whether these findings hold for older adolescents and young adults aged sixteen to thirty, with particular attention to opioid use disorder. The work is part of the NIH's Healing to End Addiction Long-Term initiative, reflecting a broader recognition that substance use disorder prevention may begin not in addiction medicine but in the pediatric psychiatry clinic, years before the first substance is ever used.
The implications are straightforward, if sometimes overlooked in clinical practice. A child with untreated ADHD or depression carries a significantly elevated risk of substance abuse. That same child, identified early and treated consistently with medication, carries substantially less risk. The data suggest that the path away from substance use disorder runs through early psychiatric care, not around it.
Notable Quotes
Picking it up early and treating these kids as long as they require treatment leads to a much better outcome when it comes to substance use disorders.— Timothy Wilens, MD, chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital
The Hearth Conversation Another angle on the story
The study looked at twenty-six prior studies. That's not original research—it's a review. How confident can we be in conclusions drawn from other people's work?
It's a fair question. But when you're looking at nearly six million individuals across multiple independent studies, all pointing in the same direction, the pattern becomes hard to dismiss. The strength is in the consistency. Most studies showed either benefit or no effect. None showed harm.
The biggest effect was in ADHD, and specifically when treatment started before age nine. Why does that age matter so much?
The brain is still forming its reward systems, its impulse control, its ability to self-regulate. ADHD untreated means years of that dysregulation—difficulty focusing, impulsivity, emotional instability. That creates vulnerability. Treat it early, and you're giving the developing brain a chance to wire itself more typically.
But there's a gap in the research. They found nothing on anxiety, conduct disorder, PTSD. Doesn't that weaken the claim?
It does, in a way. It means we can't say medication universally prevents substance use disorder across all psychiatric conditions. But it also means there's work to be done. The absence of evidence isn't evidence of absence—it's a map of where research needs to go next.
Parents hear "psychiatric medication for children" and often think of risk. What should they actually be thinking about?
That untreated psychiatric illness carries its own risk—a substantial one. The choice isn't between medication and safety. It's between treating the underlying condition and leaving it to compound. The data suggest treatment, especially early and sustained, tilts the odds in a child's favor.